| Patients with cardiac disease, such as angina, congestive heart
failure, or arrhythmia, should be closely monitored for worsening of
their clinical condition during initiation and continued treatment with
Rebif ®.
While Interferons do not have any known direct-acting cardiac toxicity,
during the post-marketing period, infrequent cases of congestive heart
failure, cardiomyopathy, and cardiomyopathy with congestive heart failure
have been reported in patients without known predisposition to these
events, and without other known etiologies being established.
|
